NCT03214614已完成1 期
Assessment of Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Galapagos NV
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Change versus placebo in the proportion of subjects with adverse events
研究概览
简要总结
The study is a Phase I, randomized, double-blind, placebo-controlled study evaluating multiple ascending oral doses of GLPG2451 and the combination of GLPG2451 and GLPG2222 given for 14 days in healthy male subjects.
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses of GLPG2451 given to healthy male subjects compared to placebo, as well as of multiple oral doses of the combination of GLPG2451/GLPG2222 compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male between 18 and 50 years of age inclusive, on the date of signing the Informed Consent Form (ICF).
- •A body mass index (BMI) between 18-30 kg/m2, inclusive.
- •Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration. Clinical safety laboratory test results must be within the laboratory reference ranges or test results that are outside the reference ranges need to be considered non clinically significant in the opinion of the investigator. One retest is allowed during screening period, if deemed appropriate by the investigator.
- •Liver function tests must meet the following criteria: a. Aspartate aminotransferase (AST), ALT, or alkaline phosphatase (ALP) <1.5x ULN.
- •b. Bilirubin not greater than ULN, however documented Gilbert's syndrome is acceptable but no more than one subject with confirmed Gilbert's syndrome is allowed per cohort. One retest is allowed during screening period, if deemed appropriate by the investigator.
- •Able and willing to comply with restrictions on prior and concomitant medication as described in the protocol.
- •Non-smokers and non-users of any nicotine-containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to screening. A non-user is defined as an individual who has abstained from any nicotine containing products for at least 1 year prior to the screening.
- •Negative urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) and negative alcohol breath test.
- •No evidence of lens opacity on slit lamp examination or similar system (e.g. ITrace technology).
- •Agree to the use of a highly effective method of contraception (see protocol).
- •Able and willing to sign the ICF as approved by the IEC, prior to any screening evaluations and willing to adhere to predefined prohibitions and restrictions.
排除标准
- •Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
- •Positive serology for hepatitis B virus surface antigen (HBs Ag), hepatitis C virus (HCV), or history of hepatitis from any cause with the exception of hepatitis A.
- •History of or a current immunosuppressive condition (e.g., human immunodeficiency virus [HIV] infection).
- •Clinically significant illness in the 3 months before the initial study drug administration.
- •Presence or sequelae of gastrointestinal, liver, kidney (creatinine clearance ≤80 mL/min using the Cockcroft-Gault formula; if calculated result ≤80 mL/min, a 24-hour urine collection to determine actual value can be performed) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- •History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence).
- •Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months of 5 half-lives of the drug (whichever is the longer) before the initial study drug administration.
- •Active drug or alcohol abuse (more than 3 glasses of wine or beer or equivalent/day) within 2 years prior to the initial study drug administration.
- •Participation in a drug, drug-device combination or biologic investigational research study within 12 weeks or 5 half-lives of the investigational drug (whichever is the longer) prior to initial study drug administration.
- •Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
研究组 & 干预措施
GLPG2451 multiple dose
Experimental
Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
干预措施: GLPG2451 multiple dose (Drug)
Placebo multiple dose
Placebo Comparator
Multiple doses of Placebo oral suspension
干预措施: Placebo multiple dose (Drug)
GLPG2451/GLPG2222
Experimental
Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
干预措施: GLPG2451/GLPG2222 multiple dose (Drug)
Combined Placebo multiple dose
Placebo Comparator
Multiple doses of Combined Placebo oral suspension
干预措施: Combined Placebo multiple dose (Drug)
结局指标
主要结局
Change versus placebo in the proportion of subjects with adverse events
时间窗: Between screening and 154 days after the last dose
To assess safety and tolerability of multiple ascending doses and combination of GLPG2451 with GLPG2222 versus placebo in healthy subjects
次要结局
- Time of occurrence of Cmax for GLPG2451 given alone or in combination with GLPG2222(Between screening and 154 days after the last dose)
- Area under the plasma concentration-time curve of GLPG2451 (AUC0-t) given alone or in combination with GLPG2222(Between screening and 154 days after the last dose)
- Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects(Day 1 predose and Day 14)
- Maximum observed plasma concentration of GLPG2451 (Cmax) given alone or in combination with GLPG2222(Between screening and 154 days after the last dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female SubjectsHealthyNCT02788721Galapagos NV31
终止
1 期
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive ImpairmentMild Cognitive ImpairmentAlzheimer's DiseaseNCT02573740AbbVie8
已完成
1 期
A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy ParticipantsHealthy ParticipantsNCT05651152Jazz Pharmaceuticals105
招募中
1 期
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisNCT06665165Amylyx Pharmaceuticals Inc.48
终止
1 期
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19Healthy VolunteersCOVID-19NCT05184218IGM Biosciences, Inc.26